|
|
Volumn 26, Issue 9, 2008, Pages 985-990
|
|
Toward biosimilar monoclonal antibodies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ABSEAMED;
ANTITHROMBIN;
BINOCRIT;
BLOOD CLOTTING FACTOR;
CLOTINAB;
EPOIETIN ALFA HEXAL;
ERYTHROPOIETIN;
ERYTHROPOIETIN ZETA;
ETANERCEPT;
HUMAN GROWTH HORMONE;
IMMUNOGLOBULIN;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
RECOMBINANT DNA;
RECOMBINANT ERYTHROPOIETIN;
REDITUX;
RETACRIT;
RITUXIMAB;
SILAPO;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ANEMIA;
BIOASSAY;
BIOSIMILARITY;
BIOTECHNOLOGY;
CLINICAL TRIAL;
CROHN DISEASE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG SAFETY;
DRUG SYNTHESIS;
EUROPEAN UNION;
HUMAN;
IMMUNOGENICITY;
LAW;
NOTE;
PATENT;
PHARMACOLOGICAL PARAMETERS;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RECOMBINANT DNA TECHNOLOGY;
ANTIBODIES, MONOCLONAL;
ANTIBODY SPECIFICITY;
BIOMEDICAL RESEARCH;
CHEMISTRY, PHARMACEUTICAL;
DRUG APPROVAL;
DRUG DESIGN;
DRUG INDUSTRY;
EUROPE;
HUMANS;
|
|
EID: 51349137409
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0908-985 Document Type: Note |
|
Times cited : (104)
|
|
References (26)
|
